Key Points
- Randall Moreadith sold 6,500 Serina shares on March 23 at an average of $2.86 (worth $18,590), adding to multiple recent insider disposals including a 39,000-share sale on March 19.
- SER opened at $3.03, has a 50-day SMA of $2.13 and a market capitalization of $32.69 million, and the company reported a quarterly loss of ($0.31) EPS.
- Serina Therapeutics is a biotech developing treatments for neurological diseases and pain, with lead candidate SER 252 targeting Parkinson's disease.
Serina Therapeutics, Inc. (NYSEAMERICAN:SER - Get Free Report) insider Randall Moreadith sold 6,500 shares of Serina Therapeutics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $2.86, for a total value of $18,590.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Randall Moreadith also recently made the following trade(s):
- On Thursday, March 19th, Randall Moreadith sold 39,000 shares of Serina Therapeutics stock. The shares were sold at an average price of $2.50, for a total value of $97,500.00.
- On Monday, February 2nd, Randall Moreadith sold 6,500 shares of Serina Therapeutics stock. The shares were sold at an average price of $3.03, for a total value of $19,695.00.
- On Wednesday, January 28th, Randall Moreadith sold 6,500 shares of Serina Therapeutics stock. The stock was sold at an average price of $3.57, for a total value of $23,205.00.
- On Thursday, January 22nd, Randall Moreadith sold 2,500 shares of Serina Therapeutics stock. The stock was sold at an average price of $2.95, for a total value of $7,375.00.
- On Wednesday, January 21st, Randall Moreadith sold 2,000 shares of Serina Therapeutics stock. The shares were sold at an average price of $3.00, for a total transaction of $6,000.00.
Serina Therapeutics Price Performance
SER stock opened at $3.03 on Thursday. The stock has a market capitalization of $32.69 million, a P/E ratio of -1.62 and a beta of 1.25. Serina Therapeutics, Inc. has a one year low of $1.22 and a one year high of $7.92. The business's 50 day simple moving average is $2.13.
Serina Therapeutics (NYSEAMERICAN:SER - Get Free Report) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.31) earnings per share (EPS) for the quarter.
Serina Therapeutics Company Profile
(
Get Free Report)
Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
